EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
1 Assignment
0 Petitions
Accused Products
Abstract
Ex-vivo methods of expanding hematopoietic stem cells of hematopoietic mononuclear cells that comprise a major fraction of hematopoietic committed cells and a minor fraction of hematopoietic stem and progenitor cells, expanded populations of hematopoietic stem cells obtained thereby and their uses are disclosed.
114 Citations
242 Claims
-
1-200. -200. (cancelled).
-
201. A method of expanding an ex-vivo population of hematopoietic stem cells, while at the same time, substantially inhibiting differentiation of the hematopoietic stem cells ex-vivo, the method comprising
providing hematopoietic mononuclear cells; -
culturing said mononuclear cells ex-vivo under conditions allowing for cell proliferation and, at the same time, culturing said cells under conditions selected from the group consisting of conditions reducing expression and/or activity of CD38 in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to retinoic acid, retinoids and/or Vitamin D in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said mononuclear cells;
culturing said mononuclear cells in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite in said mononuclear cells;
conditions reducing an expression and/or activity of PI 3-kinase in said mononuclear cells; and
culturing said mononuclear cells in the presence of at least one copper chelator or chelate, thereby expanding a population of said hematopoietic stem cells while at the same time substantially inhibiting differentiation of said hematopoietic stem cells ex-vivo. - View Dependent Claims (209, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 235, 238, 239)
-
-
202. A method of transplanting or implanting hematopoietic cells, the method comprising:
-
(a) obtaining hematopoietic mononuclear cells;
(b) culturing said mononuclear cells ex vivo for cell proliferation, wherein said culturing is performed in a condition selected from the group consisting of reducing expression and/or activity of CD38, reducing a capacity of said hematopoietic mononuclear cells in responding to retinoic acid, retinoids and/or Vitamin D, reducing capacity of said hematopoietic mononuclear cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor;
the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite;
reducing an expression and/or activity of PI 3-kinase or the presence of at least one copper chelator or chelate, thereby expanding a population of said hematopoietic stem cells, while at the same time, substantially inhibiting differentiation of said hematopoietic stem cells ex-vivo; and
(c) transplanting or implanting said hematopoietic stem cells to a recipient. - View Dependent Claims (203)
-
-
204. A method of genetically modifying hematopoietic stem cells with an exogene comprising:
-
(a) obtaining hematopoietic mononuclear cells;
(b) culturing said mononuclear cells ex vivo for cell proliferation, wherein said culturing is performed in a condition selected from the group consisting of conditions reducing expression and/or activity of CD38 in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to retinoic acid, retinoids and/or Vitamin D in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said mononuclear cells;
culturing said mononuclear cells in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite in said mononuclear cells;
conditions reducing an expression and/or activity of PI 3-kinase in said mononuclear cells; and
culturing said mononuclear cells in the presence of at least one copper chelator or chelate, thereby expanding a population of said hematopoietic stem cells, while at the same time, substantially inhibiting differentiation of said hematopoietic stem cells ex-vivo; and
(c) genetically modifying said hematopoietic stem cells with the exogene. - View Dependent Claims (205, 206)
-
-
207. A method of adoptive immunotherapy comprising:
-
(a) obtaining hematopoietic mononuclear cells from a recipient;
(b) culturing said mononuclear cells ex vivo for cell proliferation, wherein said culturing is performed in a condition selected from the group consisting of conditions reducing expression and/or activity of CD38 in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to retinoic acid, retinoids and/or Vitamin D in said mononuclear cells, conditions reducing capacity of said hematopoietic mononuclear cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said mononuclear cells;
culturing said mononuclear cells in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite in said mononuclear cells;
conditions reducing an expression and/or activity of PI 3-kinase in said mononuclear cells; and
culturing said mononuclear cells in the presence of at least one copper chelator or chelate, thereby expanding a population of said hematopoietic stem cells, while at the same time, substantially inhibiting differentiation of said hematopoietic stem cells; and
(c) transplanting said hematopoietic stem cells to the recipient.
-
-
208. A transplantable hematopoietic cell preparation comprising an expanded population of hematopoietic stem cells propagated ex-vivo from hematopoietic mononuclear cells in the presence of an effective amount of an agent,
wherein said agent has an activity selected from the group consisting of reducing expression and/or activity of CD38 in said mononuclear cells, reducing capacity of said hematopoietic mononuclear cells in responding to retinoic acid, retinoids and/or Vitamin D in said mononuclear cells, reducing capacity of said hematopoietic mononuclear cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said mononuclear cells; - and
reducing an expression and/or activity of PI 3-kinase in said mononuclear cells;
or wherein said agent isa copper chelator or chelate, or nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite in said mononuclear cells;
while at the same time, substantially inhibiting differentiation of said hematopoietic stem cells, and a pharmaceutically acceptable carrier. - View Dependent Claims (216, 232, 233, 234, 236, 237)
- and
-
240. An assay for determining whether a transition metal chelate or chelator causes substantial inhibition or induction of differentiation of hematopoietic stem cells, the assay comprising:
culturing hematopoietic mononuclear cells in the presence of the transition metal chelate or chelator and monitoring differentiation of said hematopoietic stem cells, wherein if differentiation is increased as is compared to non-treated hematopoietic mononuclear cells, said transition metal chelate induces differentiation, whereas if differentiation is decreased as is compared to non-treated hematopoietic mononuclear cells, or if differentiation is absent altogether, said transition metal chelate inhibits differentiation.
-
241. An assay for identifying an effective hematopoietic stem cell expansion agent, the assay comprising culturing hematopoietic mononuclear cells in the presence of a compound selected from the group consisting of
a retinoic acid receptor antagonist; -
retinoid X receptor antagonist;
vitamin D receptor antagonist;
agent that inhibits PI 3-kinase activity; and
a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, and monitoring expansion of said hematopoietic stem cells, wherein if increased expansion and decreased differentiation of said hematopoietic stem cells occurs, as compared to non-treated hematopoietic mononuclear cells, the compound is an effective hematopoietic stem cell expansion agent.
-
-
242. A hematopoietic stem cells collection/culturing bag supplemented with an effective amount of a compound selected from the group consisting of
a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist, nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite; - or
an agent that inhibits PI 3-kinase activity, which substantially inhibits cell differentiation of a hematopoietic stem cells fraction of hematopoietic mononuclear cells.
- or
Specification